Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Dr Qin on Choosing Between Targetable Agents in EGFR Exon 20–Mutated Lung Cancer

August 14th 2023

Angel Qin, MD, discusses her process when choosing between targetable agents for patients with EGFR exon 20–mutated lung cancer.

FDA Grants Orphan Drug Designation to Quratusugene Ozeplasmid for Small Cell Lung Cancer

August 14th 2023

The FDA has granted an orphan drug designation to quratusugene ozeplasmid (Reqorsa) for the treatment of patients with small cell lung cancer.

BAT8006 Elicits Disease Control, Safety in Advanced Ovarian Cancer and Other Solid Tumors

August 14th 2023

Treatment with the folate receptor–α antibody-drug conjugate BAT8006 led to responses with a manageable safety profile in patients with advanced solid tumors, including ovarian cancer, breast cancer, and cervical cancer.

Novel and Emerging Frontline Treatment Strategies in SCLC

August 14th 2023

Before closing out their first module, expert oncologists consider novel treatment strategies and agents in the frontline setting of stage small cell lung cancer.

Novel Treatment Approaches for SCLC and Future Perspectives

August 14th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Real-World Data and Observed AEs With Frontline Chemo IO Therapy in SCLC

August 14th 2023

Laurent Greiller, MD, and Christian Grohé, MD, consider real-world data and adverse events observed with frontline chemoimmunotherapy in small cell lung cancer.

Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond

August 11th 2023

Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC

August 11th 2023

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC

August 10th 2023

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Dr Stockhammer on Gene Alterations and Poor Outcomes in EGFR-Mutant Lung Cancer

August 10th 2023

Paul Stockhammer, MD, PhD, discusses research into the association between alterations in multiple tumor suppressor genes and poorer outcomes in patients with EGFR-mutant lung cancer, which was presented at the 2023 ASCO Annual Meeting.

Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

August 9th 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC

August 9th 2023

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

FDA Grants Regular Approval to Pralsetinib for Metastatic RET Fusion+ NSCLC

August 9th 2023

The FDA has granted regular approval to pralsetinib (Gavreto) for adult patients with metastatic RET fusion–positive non–small cell lung cancer, as detected by an FDA-approved test.

Experts Provide Key Perspectives on the US Cisplatin/Carboplatin Shortage

August 8th 2023

Experts from various institutions were interviewed by OncLive® at the 24th Annual International Lung Cancer Congress® about the ongoing platinum chemotherapy shortage in the United States.

Cisplatin/Carboplatin Shortages Underscore Need for Strategies to Prevent Future Cancer Drug Disruptions

August 8th 2023

Balazs Halmos, MD, explains why a national effort is needed to mitigate current and future drug shortages in oncology and discusses strategies being used to navigate the current cisplatin and carboplatin shortages.

Dr Kim on the Effects of Drug Shortages in Cancer Care and How to Mitigate Them

August 7th 2023

Edward S. Kim, MD, MBA, discusses drug shortages in cancer care, detailing how City of Hope has continued to establish efforts to mitigate the effects of these shortages.

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023

Dr Danish discusses barriers to using radiotherapy for the treatment of patients with metastatic lung and bone cancers; the novel capabilities of SCINTIX biology-guided technology; and how John Theurer Cancer Center plans to use this technology and help advance its role in the field of radiation oncology.

Data With TTFields Raise Questions Around the Future of Immunotherapy in Metastatic NSCLC

August 7th 2023

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.

2L Dosing Considerations and Management Strategies for SCLC

August 7th 2023

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.